annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 5B Beyond KRAS: The quest for novel genetic markers predictive for response
to anti-epidermal growth factor receptor (EGFR) therapy in patients with
metastatic colorectal cancer (mCRC). (Abstract #3567)
A. Sood, D. McClain, R. Seetharam, M. Al-rahamneh, A. Kaubisch, L. Rajdev,
K. Tanaka, J. Mariadason, S. Goel
Brd. 5C Relationship between K-Ras mutational status and EGFR expression
evaluated using Allred score in primary and metastatic colorectal cancer.
(Abstract #3568)
E. Melucci, S. Conti, M. G. Diodoro, A. Torsello, M. Zeuli, B. Casini, C. Ercolani,
F. Cognetti, C. Garufi, M. Mottolese
Brd. 5D Economic impact in the management of dermatologic toxicities (dTs)
induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab
in colorectal cancer. (Abstract #3569)
J. H. Borovicka, M. F. Mulcahy, C. Calahan, D. P. West, M. E. Lacouture
Brd. 5E Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the
association of KRAS and BRAF biomarker status with treatment outcome.
(Abstract #3570)
E. Van Cutsem, I. Lang, G. Folprecht, M. Nowacki, C. Barone, I. Shchepotin,
J. Maurel, D. Cunningham, I. Celik, C. Kohne
Brd. 5F Impact of the amount of tumor cells in tissue samples for detection of KRAS
mutations in colorectal cancer. (Abstract #3571)
J. Selves, D. Grand, R. Guimbaud, K. Gordien, S. Valmary, E. Delabesse,
M. Danjoux, E. Tournier, S. Kirzin, P. Brousset
Brd. 5G KRAS mutation testing in patients with metastatic colorectal carcinoma: An
18-month experience emphasizing the risk of false-negative results.
(Abstract #3572)
F. Bibeau, H. Frugier, E. Crapez, P. Lamy, M. Ychou, F. Boissière-Michot
Brd. 5H Cetuximab every second week with irinotecan in patients with metastatic
colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS
mutation status and efficacy. (Abstract #3573)
B. V. Jensen, J. V. Schou, H. H. Johannesen, I. J. Christensen, D. Nielsen,
J. S. Johansen, E. V. Høgdall, O. Larsen, M. Yilmaz, P. Pfeiffer
Brd. 6A Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of
angiogenesis-targeting therapy in colorectal cancer: Novel clinical
observation based upon recently discovered CEA biology. (Abstract #3574)
K. H. Bramswig, G. W. Prager, A. Martel, G. Heinze, B. R. Binder, T. Brodowicz,
G. Kornek, W. Scheithauer, C. Zielinski
Brd. 6B Bevacizumab-induced changes in small arterial dilatation measured in vivo
by dynamic retinal vessel analysis. (Abstract #3575)
G. Folprecht, K. Trautmann, M. Reimann, R. Haase, F. Ziemssen, G. Ehninger,
H. Reichmann, T. Ziemssen
Brd. 6C Gene expression profiles to predict outcome following liver resection in
patients with metastasis of colorectal cancer. (Abstract #3576)
H. Ito, Q. Mo, A. V. Maker, Q. Li-Xuan, P. Allen, R. P. DeMatteo, Y. Fong,
L. H. Blumgart, W. R. Jarnagin, M. I. D’Angelica
Brd. 6D Handy prognostic model in patients with oxaliplatin-based or irinotecanbased
first-line chemotherapy for metastatic colorectal cancer. (Abstract
#3577)
B. Chibaudel, C. Tournigand, F. Bonnetain, T. Andre, G. Lledo, F. Maindrault-
Goebel, A. K. Larsen, C. Louvet, A. de Gramont
Brd. 6E Selecting colorectal cancer (CRC) patients for therapy based on mutational
analysis by next generation sequencing: Are we analyzing the appropriate
tumor? (Abstract #3578)
J. S. Vermaat, I. J. Nijman, F. L. Gerritse, M. Mokry, W. M. Roessingh,
M. Koopman, P. J. van Diest, E. Cuppen, E. E. Voest
259
SUNDAY